Encore: Episode 3 November 9th Annual 2021 C. diff. Conference
Update: 2022-08-02
Description
This is a wonderful opportunity to listen and learn from world-renown topic leaders from the 9th Annual International C. diff. Conference & Health EXPO November 4-5, 2021.
Episode 3
Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis.
Florence Sejourne (Speaker) CEO, DA VOLTERRA
---
“Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies”
Beth Guthmueller (Speaker) Rebiotix, a Ferring Company
---
‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI’
Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics
---
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
Episode 3
Update on the Development of Gut Microbiome Protectors from Antibiotic-Induced Dysbiosis.
Florence Sejourne (Speaker) CEO, DA VOLTERRA
---
“Safety and Efficacy of Investigational Microbiota-Based Live Biotherapeutic RBX2660 in Patients with Recurrent Clostridioides difficile Infection: A Data Summary From Five Prospective Studies”
Beth Guthmueller (Speaker) Rebiotix, a Ferring Company
---
‘CP101, an Investigational Orally Administered Microbiome Therapeutic Designed to Prevent Recurrent CDI’
Shrish Budree (Speaker) Medical Director, Head of Clinical Microbiome Science, Finch Therapeutics
---
We thank ACURX Pharmaceuticals for being the Audio Sponsor of the 9th Annual Int'l C. diff. Conference & Health EXPO.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
x
